Minimally Invasive Surgeries And Robotics Will Boost Global Healthcare

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

10 Sep 24

Updated

06 Dec 25

Views

95

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-43.5%

7D

-0.6%

Loading

1Y

-43.5%

7D

-0.6%

You can edit this narrative until Dec 7 4:05 AM. Then, changes will post as Updates.

Author's Valuation

US$5425.3% undervalued

AnalystConsensusTarget Fair Value

Shared on 06 Dec 25

CNMD: Margin Expansion And Buyback Program Will Drive Strong Future Returns

Analysts have nudged their price target on CONMED slightly higher to $54, citing modestly lower discount rate and revenue growth assumptions, offset by a slightly improved profit margin outlook and a marginally lower future P/E multiple that together support a stable valuation profile. Analyst Commentary Analyst views on CONMED remain balanced, with recent model tweaks reflecting a more nuanced outlook on growth, profitability, and valuation.

Shared on 22 Nov 25

Fair value Decreased 3.57%

CNMD: Margin Initiatives And Robust Buyback Will Drive Long-Term Shareholder Value

CONMED's analyst price target has been reduced from $56 to $54 per share, as analysts cite modest cuts to growth and profit outlooks, along with slightly higher discount rates following recent sector updates. Analyst Commentary Analysts have provided a range of perspectives on CONMED’s outlook based on recent developments in company performance and sector trends.

Shared on 07 Nov 25

Fair value Decreased 8.20%

CNMD: Improving Profit Margins And Robust Buyback Program Will Drive Shareholder Value

CONMED's analyst price target has been lowered from $61 to $56. This change reflects a more cautious stance as analysts point to expectations of slower revenue growth and a higher discount rate, despite improvements in underlying profit margins and future valuation multiples.

Shared on 04 Aug 25

Fair value Decreased 8.41%

Despite improved profitability reflected in a higher net profit margin, CONMED’s valuation has compressed with a lower future P/E, leading analysts to reduce their consensus price target from $66.60 to $61.00. What's in the News CONMED Corporation raised its full-year 2025 revenue guidance to a range of $1.356 billion to $1.378 billion.

Shared on 30 Apr 25

Fair value Decreased 14%

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 0.59%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 11 Mar 25

Fair value Increased 15%

AnalystConsensusTarget has decreased revenue growth from 5.9% to 5.3%, decreased profit margin from 12.0% to 10.5% and increased future PE multiple from 15.7x to 18.7x.

AnalystConsensusTarget Fair Value

US$54

25.3% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

4.48%

Medical Equipment revenue growth rate

8.16%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

9.20%

Calculation

US$168.71m

Earnings '28

x

12.89x

PE Ratio '28

=

US$2.17b

Market Cap '28

US$2.17b

Market Cap '28

/

31.15m

No. shares '28

=

US$69.80

Share Price '28

US$69.80 Share Price '28

Discounted to 2025 @ 9.10% p.a.

=

US$53.75

Fair Value '25